Filing Flows › Celularity (CELU) › Q2 2026 › vs Q1 2026
Celularity (CELU) Q2 2026 vs Q1 2026 (quarter over quarter)
Celularity's revenue rose $1.6M (+41%) from $3.8M in Q1 2026 to $5.4M in Q2 2026. The biggest changes: Product +$3.2M (+369%); License Royalty and Other −$1.0M (-58%); Service −$598K (-48%).
Celularity, Q2 2026: revenue $5.4M (-5% year over year), operating margin -78.0%, net earnings $706K, operating cash flow −$1.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $4.1M | $866K | $3.2M | +369% |
| License Royalty and Other | $719K | $1.7M | −$1.0M | -58% |
| Service | $652K | $1.2M | −$598K | -48% |
| Revenue | $5.4M | $3.8M | $1.6M | +41% |
| Other income, net | $4.9M | $11.0M | −$6.1M | -55% |
| Costs & expenses | $10.4M | $14.9M | −$4.5M | -30% |
| Operating costs | $9.7M | $14.0M | −$4.3M | -31% |
| Net earnings | $706K | $874K | −$168K | -19% |
| Cost of revenue | $2.3M | $1.5M | $895K | +62% |
| Research & development | $2.0M | $3.0M | −$966K | -32% |
| SG&A | $4.9M | $9.2M | −$4.2M | -46% |
| Other operating costs | $354K | $368K | −$14K | -4% |
| Operating cash sources | $4.2M | $2.3M | $1.9M | +85% |
| Depreciation & amortization | $1.5M | $1.6M | −$58K | -4% |
| Share-based compensation | $844K | $1.2M | −$399K | -32% |
| Cash used in operations | $1.1M | −$1.4M | $2.6M | — |
| Working capital & other | $4.2M | $2.3M | $1.9M | +85% |
Questions
How much did Celularity's revenue grow quarter over quarter in Q2 2026?
Celularity's revenue rose $1.6M (+41%) from $3.8M in Q1 2026 to $5.4M in Q2 2026.
What drove Celularity's revenue change in Q2 2026?
Product +$3.2M (+369%); License Royalty and Other −$1.0M (-58%); Service −$598K (-48%).